Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05130528 · ClinicalTrials.gov registry record · NA

Therapeutic Intervention Supporting Development From NICU to 6 Months for Infants Post Hypoxic-Ischemic Encephalopathy

A NA study of Cerebral Palsy and Hypoxic Ischemic Encephalopathy, sponsored by University of Southern California.

Completed
Registry status
NA
Development phase
12
Enrollment target
2
Study locations

NCT05130528 is a NA study of Cerebral Palsy and Hypoxic Ischemic Encephalopathy that has completed, run by University of Southern California. The registered enrollment target is 12 participants, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05130528, a NA study of Cerebral Palsy and Hypoxic Ischemic Encephalopathy, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the feasibility and begin to evaluate the effect of a sensorimotor intervention (SMI) provided in the first 6 months of life for infants with hypoxic-ischemic encephalopathy.

Interventions

  • BEHAVIORAL Sensorimotor Intervention

Study Locations (2)

California

  • Children's Hospital Los Angeles - Los Angeles
  • University of Southern California - Los Angeles

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-02-18
Est. Completion 2024-04-30
Phase NA

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT05130528

The ClinicalTrials.gov registry entry for NCT05130528 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (95% lower). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 1 intervention - of which Sensorimotor Intervention is the first listed.

NCT05130528 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05130528 about?

NCT05130528 is a clinical study titled "Therapeutic Intervention Supporting Development From NICU to 6 Months for Infants Post Hypoxic-Ischemic Encephalopathy". The purpose of this study is to evaluate the feasibility and begin to evaluate the effect of a sensorimotor intervention (SMI) provided in the first 6 months of life for infants with hypoxic-ischemic encephalopathy.

What is the current status of trial NCT05130528?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-02-18. Estimated completion is 2024-04-30.

What conditions does trial NCT05130528 study?

This clinical trial studies the following conditions: Cerebral Palsy, Hypoxic Ischemic Encephalopathy.

What interventions are being tested in trial NCT05130528?

The interventions under investigation include: Sensorimotor Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT05130528?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05130528 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.